By: Tracy Staton
29 November 2010
GlaxoSmithKline has teamed up with another emerging markets partner. The drugmaker inked a deal with Russian vaccine firm JSC Binnopharm to make and sell several of its big vaccines in that country. It’s just the latest in a series of tie-ups in developing countries for GSK, which is pinning a big chunk of its growth hopes on those fast-growing drug markets.
GSK will supply bulk vaccine to Binnopharm, along with expertise and technology. Binnopharm will be responsible for getting government approval for the vaccines–the human papilloma virus/cervical cancer shot Cervarix; the rotavirus vaccine Rotarix; and the pneumococcal vaccine Synflorix–and for amping up its manufacturing facilities for the purpose. Financial details weren’t disclosed.